Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Estimated Market Size and CAGR of the Neuromyelitis Optica Spectrum Disorder Market for the Period 2025–2029?
The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.54 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), rising awareness and early diagnosis, rising therapeutic options and FDA approvals, growing research and development activities, and rising clinical trials for novel therapies.
The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to " $3.49 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, increasing healthcare expenditure, rising investments in research and development, increasing prevalence of autoimmune diseases, increasing clinical trials for NMOSD therapies, and growing demand for personalized medicine. Major trends in the forecast period include advancements in precision medicine, collaboration & partnerships, technological innovations, integration of AI & big data in research, and a shift towards home-based treatments.
Get your free report sample today:
Which Core Drivers Are Expected to Drive Demand Within the Neuromyelitis Optica Spectrum Disorder Market?
The increasing prevalence of multiple sclerosis is expected to propel the growth of the neuromyelitis optica spectrum disorder market going forward. Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system, causing inflammation, nerve damage, and neurological symptoms. The increasing prevalence of multiple sclerosis is due to improvising diagnostic techniques, environmental influences, and genetic predisposition. Advancements in medical imaging, such as MRI, have allowed for earlier and more accurate diagnoses, leading to an apparent rise in cases. As more individuals are diagnosed with MS, there is a heightened awareness of neurological autoimmune diseases, leading to improved diagnostic methods and greater recognition of neuromyelitis optica spectrum disorder. For instance, in May 2024, according to the Multiple Sclerosis Trust, a UK-based national charity, the UK sees approximately 7,100 new multiple sclerosis cases annually, and some 135 persons are diagnosed with MS each week. Therefore, the increasing prevalence of multiple sclerosis drives the growth of the neuromyelitis optica spectrum disorder market.
What Are the Primary Market Segments in the Neuromyelitis Optica Spectrum Disorder Market?
The neuromyelitis optica spectrum disordermarket covered in this report is segmented –
1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies; Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies
2) By Diagnosis: Imaging Tests; Magnetic Resonance Imaging (MRI); Blood Tests; Others Diagnosis
3) By Treatment Type: C5 Protein Inhibitor; Monoclonal Antibodies; Plasma Exchange Therapy; Corticosteroids; Immunoglobulin Therapy; Medication; Other Treatment Types
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies: Relapsing NMOSD with AQP4-IgG; Monophasic NMOSD with AQP4-IgG; Severe Optic Neuritis with AQP4-IgG; Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG
2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG); Seronegative NMOSD; Idiopathic NMOSD Cases; NMOSD Associated With Other Autoimmune Disorders
What Are the Current Trends Influencing the Neuromyelitis Optica Spectrum Disorder Market?
Major companies operating in the neuromyelitis optica spectrum disorder market are focusing on developing innovative products, such as long-acting complement inhibitors, to enhance treatment efficacy and improve patient outcomes. Long-acting complement inhibitors are treatments that suppress the complement system for an extended duration, preventing inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD). They help minimize relapses and support long-term disease control. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical industry, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This approval marks Ultomiris as the first and only long-acting C5 complement inhibitor available for NMOSD treatment. The decision was based on the Phase III CHAMPION-NMOSD trial, where Ultomiris demonstrated a 98.6% reduction in relapse risk over 73 weeks compared to a placebo. Trial participants experienced no relapses, and no new safety concerns were identified.
Who Are the Major Companies Operating in the Neuromyelitis Optica Spectrum Disorder Market?
Major companies operating in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics
Get the detailed neuromyelitis optica spectrum disorder market report today
Which Region Holds the Largest Share of the Neuromyelitis Optica Spectrum Disorder Market?
North America was the largest region in the neuromyelitis optica spectrum disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromyelitis optica spectrum disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment